NIS2 for Pharma and Medical Device Companies: Key Requirements for 2026

The Context: How NIS2 Is Reshaping the Life Sciences Industry

The implementation of the NIS2 Directive across the European Union is an important step in the evolution of cybersecurity and operational resilience in many high-risk industries. While organizations continue to prepare for new requirements and enforcement measures, the directive signals a shift from a largely compliance-driven approach to one built on accountability, governance, risk management, and oversight.

For pharmaceutical and medical device organizations, this means operating in a more demanding environment, with increased expectations around cybersecurity, supply chain, riskmanagement, and executive responsibility for compliance. 

What Does the NIS2 Directive Require?

The directive introduces clear expectations for cybersecurity risk management, protection of critical infrastructure, business continuity, incident response, and the reporting of significant cybersecurity incidents.

A defining feature of NIS2 is the strengthened role of national competent authorities across EU Member States and a more robust enforcement framework. Important to mention, that the directive introduces substantial penalties for non-compliance, making cybersecurity also a strategic governance priority that requires active involvement from senior leadership.

 

Who Does NIS2 Apply To?

One of the most common questions surrounding NIS2 is its scope of applicability. Within the Life Sciences sector, the directive covers a broad range of organizations considered important to public health, healthcare systems, and economic stability.

Companies may fall within the scope of NIS2 as Essential or Important Entities, depending on their activities, role within the supply chain, and applicable national legislation, including manufacturers, diagnostic companies, CDMOs, and providers of critical ICT services. As a result, NIS2 extends cybersecurity and resilience requirements across the entire supply chain, significantly broadening the range of organizations affected compared to previous regulations.

 

NIS2 Compliance Timelines 

As NIS2 implementation continues across EU Member States, 2026 represents a key period for many organizations to strengthen their compliance and cybersecurity maturity programs. Activities include the identification of critical services and assets, supplier risk assessments, governance enhancements, cybersecurity program maturity reviews, and implementation of required security measures.

Establishing clear accountability structures, strengthening incident response capabilities, and ensuring appropriate management oversight of cybersecurity risks are key expectations for these organizations.

While specific implementation timelines and reporting obligations may vary across Member States, an effective implementation program creates the foundation long-term and reduces the risk of costly corrective actions later on.

 

NIS2 and Supply Chain Security: A Critical Challenge

Supply chain security is one of the significant aspects of the NIS2 Directive, requiring organizations to assess, manage, and continuously monitor cybersecurity risks associated with suppliers and third-party service providers.

For Life Sciences organizations, this can be particularly challenging. In addition to ICT providers, companies must evaluate a wide range of critical partners, including CMO/CDMO networks, GxP-regulated systems such as LIMS, MES, and ERP platforms, logistics providers, cloud service providers, and clinical technology partners.

In order to successfully address these requirements, they shall combine cybersecurity expertise, industry specific knowledge, and a structured compliance framework capable of integrating operational, quality, and regulatory considerations, helping organizations advance their NIS2 compliance objectives.

 

How to Achieve NIS2 Compliance 

Successfully aligning with NIS2 requires a structured and phased approach.

Most organizations begin with a NIS2 gap assessment to identify areas requiring improvement and establish a practical compliance roadmap. A key advantage lies in leveraging existing compliance frameworks such as GxP, GAMP® 5 Second Edition, and Annex 11. Furthermore, integrating NIS2 requirements within established quality and compliance processes can help avoid duplication, reduce implementation effort, and create a more efficient and sustainable compliance model. When done properly, cybersecurity becomes a strategic enabler of business continuity.

 

Final thoughts

The NIS2 Directive represents a significant milestone for the pharmaceutical and medical device industries. With broader applicability, increased accountability, and more rigorous cybersecurity requirements, organizations are being challenged to rethink how they approach risk, resilience, and compliance.

NIS 2_Blog

Need support with your NIS2 local adaptation?

PQE Group's cybersecurity, quality, and compliance experts can help you assess your readiness, identify gaps, and build a practical roadmap to compliance.


Talk to an Expert  Discover Our Services